Recent therapeutic advances in juvenile idiopathic arthritis

Gabriella Giancane, Alessandra Alongi, Silvia Rosina, Jessica Tibaldi, Alessandro Consolaro, Angelo Ravelli

Research output: Contribution to journalReview article

Abstract

Over the past two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by the increased tendency toward early aggressive interventions and the availability of the novel biologic medications. In 2017, three novel randomized controlled trials have evaluated the effectiveness and tolerability of golimumab and tocilizumab in polyarticular JIA, and shown that methotrexate may increase and prolong the effect of intra-articular corticosteroid injection in children with oligoarthritis. A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans, and advice for the optimal care. A few months ago, an international consensus effort has led to the development of the recommendations for the treat-to-target in JIA. The application of this strategy in routine care may improve disease outcome. Because the potential of attaining inactive disease in children with JIA has markedly increased, there is an urgent need for randomized controlled trials, analyses of clinical data sets, and expert advice to guide discontinuation of medications once complete disease quiescence has been achieved.

Original languageEnglish
Pages (from-to)476-487
Number of pages12
JournalBest Practice and Research in Clinical Rheumatology
Volume31
Issue number4
DOIs
Publication statusPublished - Aug 2017

Fingerprint

Juvenile Arthritis
Randomized Controlled Trials
Therapeutics
Intra-Articular Injections
Methotrexate
Biological Availability
Adrenal Cortex Hormones

Keywords

  • Antibodies, Monoclonal/therapeutic use
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Antirheumatic Agents/therapeutic use
  • Arthritis, Juvenile/drug therapy
  • Child
  • Glucocorticoids/therapeutic use
  • Humans
  • Injections, Intra-Articular
  • Methotrexate/therapeutic use
  • Treatment Outcome

Cite this

Recent therapeutic advances in juvenile idiopathic arthritis. / Giancane, Gabriella; Alongi, Alessandra; Rosina, Silvia; Tibaldi, Jessica; Consolaro, Alessandro; Ravelli, Angelo.

In: Best Practice and Research in Clinical Rheumatology, Vol. 31, No. 4, 08.2017, p. 476-487.

Research output: Contribution to journalReview article

@article{7142a89fde4b4c62b45f3ef07490e391,
title = "Recent therapeutic advances in juvenile idiopathic arthritis",
abstract = "Over the past two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by the increased tendency toward early aggressive interventions and the availability of the novel biologic medications. In 2017, three novel randomized controlled trials have evaluated the effectiveness and tolerability of golimumab and tocilizumab in polyarticular JIA, and shown that methotrexate may increase and prolong the effect of intra-articular corticosteroid injection in children with oligoarthritis. A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans, and advice for the optimal care. A few months ago, an international consensus effort has led to the development of the recommendations for the treat-to-target in JIA. The application of this strategy in routine care may improve disease outcome. Because the potential of attaining inactive disease in children with JIA has markedly increased, there is an urgent need for randomized controlled trials, analyses of clinical data sets, and expert advice to guide discontinuation of medications once complete disease quiescence has been achieved.",
keywords = "Antibodies, Monoclonal/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Antirheumatic Agents/therapeutic use, Arthritis, Juvenile/drug therapy, Child, Glucocorticoids/therapeutic use, Humans, Injections, Intra-Articular, Methotrexate/therapeutic use, Treatment Outcome",
author = "Gabriella Giancane and Alessandra Alongi and Silvia Rosina and Jessica Tibaldi and Alessandro Consolaro and Angelo Ravelli",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2017",
month = "8",
doi = "10.1016/j.berh.2018.01.001",
language = "English",
volume = "31",
pages = "476--487",
journal = "Best Practice and Research in Clinical Rheumatology",
issn = "1521-6942",
publisher = "Bailliere Tindall Ltd",
number = "4",

}

TY - JOUR

T1 - Recent therapeutic advances in juvenile idiopathic arthritis

AU - Giancane, Gabriella

AU - Alongi, Alessandra

AU - Rosina, Silvia

AU - Tibaldi, Jessica

AU - Consolaro, Alessandro

AU - Ravelli, Angelo

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2017/8

Y1 - 2017/8

N2 - Over the past two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by the increased tendency toward early aggressive interventions and the availability of the novel biologic medications. In 2017, three novel randomized controlled trials have evaluated the effectiveness and tolerability of golimumab and tocilizumab in polyarticular JIA, and shown that methotrexate may increase and prolong the effect of intra-articular corticosteroid injection in children with oligoarthritis. A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans, and advice for the optimal care. A few months ago, an international consensus effort has led to the development of the recommendations for the treat-to-target in JIA. The application of this strategy in routine care may improve disease outcome. Because the potential of attaining inactive disease in children with JIA has markedly increased, there is an urgent need for randomized controlled trials, analyses of clinical data sets, and expert advice to guide discontinuation of medications once complete disease quiescence has been achieved.

AB - Over the past two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by the increased tendency toward early aggressive interventions and the availability of the novel biologic medications. In 2017, three novel randomized controlled trials have evaluated the effectiveness and tolerability of golimumab and tocilizumab in polyarticular JIA, and shown that methotrexate may increase and prolong the effect of intra-articular corticosteroid injection in children with oligoarthritis. A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans, and advice for the optimal care. A few months ago, an international consensus effort has led to the development of the recommendations for the treat-to-target in JIA. The application of this strategy in routine care may improve disease outcome. Because the potential of attaining inactive disease in children with JIA has markedly increased, there is an urgent need for randomized controlled trials, analyses of clinical data sets, and expert advice to guide discontinuation of medications once complete disease quiescence has been achieved.

KW - Antibodies, Monoclonal/therapeutic use

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Antirheumatic Agents/therapeutic use

KW - Arthritis, Juvenile/drug therapy

KW - Child

KW - Glucocorticoids/therapeutic use

KW - Humans

KW - Injections, Intra-Articular

KW - Methotrexate/therapeutic use

KW - Treatment Outcome

U2 - 10.1016/j.berh.2018.01.001

DO - 10.1016/j.berh.2018.01.001

M3 - Review article

C2 - 29773268

VL - 31

SP - 476

EP - 487

JO - Best Practice and Research in Clinical Rheumatology

JF - Best Practice and Research in Clinical Rheumatology

SN - 1521-6942

IS - 4

ER -